Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848767 | 0.90 | KMT2A (0.35) | SMN1; SMN2MAOBHDAC1HDAC6MEN1 | |
| SCHEMBL25848772 | 0.88 | NPC1 (0.43) | P2RX7SMN1; SMN2EPHX2MEN1KMT2A | |
| SCHEMBL25848887 | 0.88 | EPHX2 (0.45) | EPHX2NR1H4HDAC1HDAC6 | |
| SCHEMBL25848776 | 0.87 | EPHX2 (0.42) | EPHX2HDAC1HDAC6 | |
| SCHEMBL25848768 | 0.86 | KMT2A (0.39) | SMN1; SMN2HPGDHDAC1HDAC6MEN1 | |
| SCHEMBL25848757 | 0.86 | HDAC1 (0.44) | EPHX2NR1H4HPGDHDAC1HDAC6 | |
| SCHEMBL25848967 | 0.86 | TRPV1 (0.45) | EPHX2NR1H4HDAC1HDAC6KMT2A | |
| SCHEMBL25848854 | 0.85 | EPHX2 (0.45) | EPHX2NR1H4MAOBHPGDHDAC1 | |
| SCHEMBL25848766 | 0.84 | RXFP1 (0.47) | PDE10ASMN1; SMN2EPHX2MAOBHPGD | |
| SCHEMBL25848771 | 0.83 | USP5 (0.36) | P2RX7SMN1; SMN2EPHX2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | P2RX7 891/4885PDE10A 2060/4885SMN1; SMN2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.